Neuland Laboratories Ltd banner

Neuland Laboratories Ltd
NSE:NEULANDLAB

Watchlist Manager
Neuland Laboratories Ltd Logo
Neuland Laboratories Ltd
NSE:NEULANDLAB
Watchlist
Price: 15 118 INR 0.79% Market Closed
Market Cap: ₹194B

Neuland Laboratories Ltd
Note Receivable

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Neuland Laboratories Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Neuland Laboratories Ltd
NSE:NEULANDLAB
Note Receivable
₹143.3m
CAGR 3-Years
N/A
CAGR 5-Years
3%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Note Receivable
₹3.7B
CAGR 3-Years
7%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Note Receivable
₹5.4B
CAGR 3-Years
N/A
CAGR 5-Years
59%
CAGR 10-Years
7%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Note Receivable
₹2.6B
CAGR 3-Years
-51%
CAGR 5-Years
-40%
CAGR 10-Years
-21%
Lupin Ltd
NSE:LUPIN
Note Receivable
₹504.1m
CAGR 3-Years
-49%
CAGR 5-Years
-19%
CAGR 10-Years
-16%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Note Receivable
₹2.4B
CAGR 3-Years
28%
CAGR 5-Years
25%
CAGR 10-Years
2%
No Stocks Found

Neuland Laboratories Ltd
Glance View

Neuland Laboratories Ltd., with its roots firmly planted in the bustling pharmaceutical sector of India, presents a captivating narrative of innovation and strategic growth. Founded in 1984 by Dr. D.R. Rao, the venture initially embarked on its journey by manufacturing Active Pharmaceutical Ingredients (APIs), essential components that power numerous medical treatments. Situated in Hyderabad, the company swiftly carved out a niche by focusing on complex and high-value APIs, earning a reputation for quality and reliability. This strategy enabled Neuland to establish long-standing relationships with prominent generic pharmaceutical companies across the globe. As the world of pharmaceuticals evolved, so did Neuland's approach to business. The company shifted gears to not just produce APIs but also ventured into Contract Research and Manufacturing Services (CRAMS), capitalizing on the growing demand for customized pharmaceutical development and production services. This not only diversified their revenue streams but also aligned them with the needs of various pharmaceutical innovators striving for precision and customization in their drug formulations. With a commitment to regulatory compliance and a robust infrastructural foundation, Neuland Laboratories continues to bolster its position in the market, marrying its time-honored expertise in chemistry with cutting-edge technological advancements to drive profitability and sustain its international footprint.

NEULANDLAB Intrinsic Value
6 080.76 INR
Overvaluation 60%
Intrinsic Value
Price ₹15 118

See Also

What is Neuland Laboratories Ltd's Note Receivable?
Note Receivable
143.3m INR

Based on the financial report for Dec 31, 2025, Neuland Laboratories Ltd's Note Receivable amounts to 143.3m INR.

What is Neuland Laboratories Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
3%

Over the last year, the Note Receivable growth was 21%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett